Specifications
Properties
Additional Info
Background
Specifications
| SPECIES REACTIVITY: | Human, Mouse |
|---|---|
| TESTED APPLICATIONS: | ELISA, ICC, IF, IHC-P, WB |
| APPLICATIONS: | DR5 antibody can be used for detection of DR5 expression by Western blot at 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 5 μg/mL and immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 10 μg/mL. Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples; Immunocytochemistry in human samples and Immunofluorescence in human and mouse samples. All other applications and species not yet tested. |
| USER NOTE: | Optimal dilutions for each application to be determined by the researcher. |
| POSITIVE CONTROL: | 1) Cat. No. 1201 - HeLa Cell Lysate |
| 2) Cat. No. 1204 - K562 Cell Lysate | |
| 3) Cat. No. 17-001 - HeLa Cell Slide | |
| SPECIFICITY: | Antibody has no cross reaction to DR4. |
| IMMUNOGEN: | DR5 antibody was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of human DR5 precursor. The immunogen is located within the last 50 amino acids of DR5. |
| HOST SPECIES: | Rabbit |
Properties
| PURIFICATION: | DR5 Antibody is affinity chromatography purified via peptide column. |
|---|---|
| PHYSICAL STATE: | Liquid |
| BUFFER: | DR5 Antibody is supplied in PBS containing 0.02% sodium azide. |
| CONCENTRATION: | batch dependent |
| STORAGE CONDITIONS: | DR5 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| CLONALITY: | Polyclonal |
| ISOTYPE: | IgG |
| CONJUGATE: | Unconjugated |
Additional Info
| ALTERNATE NAMES: | DR5 Antibody: DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5, DR5, UNQ160/PRO186, Tumor necrosis factor receptor superfamily member 10B, Death receptor 5, TRAIL receptor 2 |
|---|---|
| ACCESSION NO.: | AF012535 |
| PROTEIN GI NO.: | 2338419 |
| OFFICIAL SYMBOL: | TNFRSF10B |
| GENE ID: | 8795 |
Background
| BACKGROUND: | DR5 Antibody: Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently. Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-κB. |
|---|---|
| REFERENCES: | 1) Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8 | 2) Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21 | 3) Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-97 | 4) MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272:25417-20 |
For Research Use Only
